Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

346.97 +7.86 (+2.32%)
Streaming Delayed Price Updated: 2:01 PM EST, Feb 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
20 21 Next >
News headline image
Alnylam Announces U.S. Food and Drug Administration (FDA) Acceptance of Supplemental New Drug Application for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2022 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Five Best And Worst Performing Healthcare Stocks In December 2022 ↗
Multiple factors are expected to help the healthcare industry overcome inflationary pressures. If you are looking to invest in this sector, then to help you select, here are the five best and worst... 
Via Talk Markets
News headline image
Alnylam's Lumasiran Scores Expanded FDA Approval For Ultra Rare Genetic Disease ↗
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023 ↗
 
Via Benzinga
News headline image
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional Updates
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
3 Growth Stocks That Could Rocket Higher in 2023 ↗
Upcoming binary events could push these stocks to new all-time highs. 
Via The Motley Fool
News headline image
Alnylam Announces Updates to its Board of Directors
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Webcast Presentation at 41st Annual J.P. Morgan Healthcare Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Submits CTA Application for ALN-KHK, an Investigational RNAi Therapeutic for the Treatment of Type 2 Diabetes
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Meta To Rally Over 29%? Here Are 10 Other Price Target Changes For Friday ↗
 
Via Benzinga
News headline image
Alnylam Announces 2023 Product and Pipeline Goals and Provides Program Updates at R&D Day
From Alnylam Pharmaceuticals
Via Business Wire
News headline image
Alnylam Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration (FDA) for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Webcast Virtual R&D Day
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims ↗
 
Via Benzinga
News headline image
Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2022
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Looking Into Alnylam Pharmaceuticals's Return On Capital Employed ↗
Benzinga Pro data, Alnylam Pharmaceuticals (NASDAQ:ALNY) reported Q3 sales of $264.31 million. Earnings fell to a loss of $405.92 million, resulting in a 46.33% decrease from last quarter. 
Via Benzinga
News headline image
What 11 Analyst Ratings Have To Say About Alnylam Pharmaceuticals ↗
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings: 
Via Benzinga
News headline image
Alnylam Recognized by Science Magazine as Top Employer for Fourth Consecutive Year
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Scraps Interim Analysis For Heart Disease Trial, Rethinks Plans For Another Rare Disorder Program ↗
 
Via Benzinga
News headline image
Alnylam Pharmaceuticals: Q3 Earnings Insights ↗
Alnylam Pharmaceuticals (NASDAQ:ALNY) reported its Q3 earnings results on Thursday, October 27, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Alnylam Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures? ↗
Despite enthusiasm in some camps, the risk of potential cures clouds market projections. 
Via Investor's Business Daily
News headline image
Where Alnylam Pharmaceuticals Stands With Analysts ↗
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings: 
Via Benzinga
News headline image
Roblox To $51? Plus Deutsche Bank Slashes PT On Deere & Company ↗
  
Via Benzinga
News headline image
Alnylam to Webcast Conference Call Discussing Third Quarter 2022 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
3 Top Biotech Stocks Defying the Bear Market ↗
Bear market, shmear market. These biotech stocks are soaring despite the market downturn. 
Via The Motley Fool
News headline image
Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Where Alnylam Pharmaceuticals Stands With Analysts ↗
Over the past 3 months, 12 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.